Irritable bowel syndrome: Recent and novel therapeutic approaches

Viola Andresen, Michael Camilleri

Research output: Contribution to journalArticle

68 Citations (Scopus)

Abstract

Irritable bowel syndrome (IBS) is a highly prevalent functional gastrointestinal disorder affecting up to 3-15% of the general population in Western countries. It is characterised by unexplained abdominal pain, discomfort and bloating in association with altered bowel habits. The pathophysiology of IBS is considered to be multifactorial, involving disturbances of the brain-gut-axis: IBS has been associated with abnormal gastrointestinal motor functions, visceral hypersensitivity, psychosocial factors, autonomic dysfunction and mucosal inflammation. Traditional IBS therapy is mainly symptom oriented and often unsatisfactory. Hence, there is a need for new treatment strategies. Increasing knowledge of brain-gut physiology, mechanisms, and neurotransmitters and receptors involved in gastrointestinal motor and sensory function have led to the development of several new therapeutic approaches. This article provides a systematic overview of recently approved or novel medications that show promise for the treatment of IBS; classification is based on the physiological systems targeted by the medication. The article includes agents acting on the serotonin receptor or serotonin transporter system, novel selective anticholinergics, α-adrenergic agonists, opioid agents, cholecystokinin antagonists, neurokinin antagonists, somatostatin receptor agonists, neurotrophin-3, corticotropin releasing factor antagonists, chloride channel activators, guanylate cyclase-c agonists, melatonin and atypical benzodiazepines. Finally, the role of probiotics and antibacterials in the treatment of IBS is summarised.

Original languageEnglish (US)
Pages (from-to)1073-1088
Number of pages16
JournalDrugs
Volume66
Issue number8
DOIs
StatePublished - 2006

Fingerprint

Irritable Bowel Syndrome
Brain
Neurotrophin 3
Somatostatin Receptors
Adrenergic Agonists
Serotonin Plasma Membrane Transport Proteins
Neurotransmitter Receptor
Guanylate Cyclase
Serotonin Receptors
Corticotropin-Releasing Hormone
Cholecystokinin
Physiology
Cholinergic Antagonists
Melatonin
Benzodiazepines
Opioid Analgesics
Therapeutics
Medication Systems
Gastrointestinal Diseases
Probiotics

ASJC Scopus subject areas

  • Health, Toxicology and Mutagenesis
  • Toxicology

Cite this

Irritable bowel syndrome : Recent and novel therapeutic approaches. / Andresen, Viola; Camilleri, Michael.

In: Drugs, Vol. 66, No. 8, 2006, p. 1073-1088.

Research output: Contribution to journalArticle

Andresen, Viola ; Camilleri, Michael. / Irritable bowel syndrome : Recent and novel therapeutic approaches. In: Drugs. 2006 ; Vol. 66, No. 8. pp. 1073-1088.
@article{6a2397653f0c4812977fde7164459b9f,
title = "Irritable bowel syndrome: Recent and novel therapeutic approaches",
abstract = "Irritable bowel syndrome (IBS) is a highly prevalent functional gastrointestinal disorder affecting up to 3-15{\%} of the general population in Western countries. It is characterised by unexplained abdominal pain, discomfort and bloating in association with altered bowel habits. The pathophysiology of IBS is considered to be multifactorial, involving disturbances of the brain-gut-axis: IBS has been associated with abnormal gastrointestinal motor functions, visceral hypersensitivity, psychosocial factors, autonomic dysfunction and mucosal inflammation. Traditional IBS therapy is mainly symptom oriented and often unsatisfactory. Hence, there is a need for new treatment strategies. Increasing knowledge of brain-gut physiology, mechanisms, and neurotransmitters and receptors involved in gastrointestinal motor and sensory function have led to the development of several new therapeutic approaches. This article provides a systematic overview of recently approved or novel medications that show promise for the treatment of IBS; classification is based on the physiological systems targeted by the medication. The article includes agents acting on the serotonin receptor or serotonin transporter system, novel selective anticholinergics, α-adrenergic agonists, opioid agents, cholecystokinin antagonists, neurokinin antagonists, somatostatin receptor agonists, neurotrophin-3, corticotropin releasing factor antagonists, chloride channel activators, guanylate cyclase-c agonists, melatonin and atypical benzodiazepines. Finally, the role of probiotics and antibacterials in the treatment of IBS is summarised.",
author = "Viola Andresen and Michael Camilleri",
year = "2006",
doi = "10.2165/00003495-200666080-00004",
language = "English (US)",
volume = "66",
pages = "1073--1088",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "8",

}

TY - JOUR

T1 - Irritable bowel syndrome

T2 - Recent and novel therapeutic approaches

AU - Andresen, Viola

AU - Camilleri, Michael

PY - 2006

Y1 - 2006

N2 - Irritable bowel syndrome (IBS) is a highly prevalent functional gastrointestinal disorder affecting up to 3-15% of the general population in Western countries. It is characterised by unexplained abdominal pain, discomfort and bloating in association with altered bowel habits. The pathophysiology of IBS is considered to be multifactorial, involving disturbances of the brain-gut-axis: IBS has been associated with abnormal gastrointestinal motor functions, visceral hypersensitivity, psychosocial factors, autonomic dysfunction and mucosal inflammation. Traditional IBS therapy is mainly symptom oriented and often unsatisfactory. Hence, there is a need for new treatment strategies. Increasing knowledge of brain-gut physiology, mechanisms, and neurotransmitters and receptors involved in gastrointestinal motor and sensory function have led to the development of several new therapeutic approaches. This article provides a systematic overview of recently approved or novel medications that show promise for the treatment of IBS; classification is based on the physiological systems targeted by the medication. The article includes agents acting on the serotonin receptor or serotonin transporter system, novel selective anticholinergics, α-adrenergic agonists, opioid agents, cholecystokinin antagonists, neurokinin antagonists, somatostatin receptor agonists, neurotrophin-3, corticotropin releasing factor antagonists, chloride channel activators, guanylate cyclase-c agonists, melatonin and atypical benzodiazepines. Finally, the role of probiotics and antibacterials in the treatment of IBS is summarised.

AB - Irritable bowel syndrome (IBS) is a highly prevalent functional gastrointestinal disorder affecting up to 3-15% of the general population in Western countries. It is characterised by unexplained abdominal pain, discomfort and bloating in association with altered bowel habits. The pathophysiology of IBS is considered to be multifactorial, involving disturbances of the brain-gut-axis: IBS has been associated with abnormal gastrointestinal motor functions, visceral hypersensitivity, psychosocial factors, autonomic dysfunction and mucosal inflammation. Traditional IBS therapy is mainly symptom oriented and often unsatisfactory. Hence, there is a need for new treatment strategies. Increasing knowledge of brain-gut physiology, mechanisms, and neurotransmitters and receptors involved in gastrointestinal motor and sensory function have led to the development of several new therapeutic approaches. This article provides a systematic overview of recently approved or novel medications that show promise for the treatment of IBS; classification is based on the physiological systems targeted by the medication. The article includes agents acting on the serotonin receptor or serotonin transporter system, novel selective anticholinergics, α-adrenergic agonists, opioid agents, cholecystokinin antagonists, neurokinin antagonists, somatostatin receptor agonists, neurotrophin-3, corticotropin releasing factor antagonists, chloride channel activators, guanylate cyclase-c agonists, melatonin and atypical benzodiazepines. Finally, the role of probiotics and antibacterials in the treatment of IBS is summarised.

UR - http://www.scopus.com/inward/record.url?scp=33745366578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745366578&partnerID=8YFLogxK

U2 - 10.2165/00003495-200666080-00004

DO - 10.2165/00003495-200666080-00004

M3 - Article

C2 - 16789793

AN - SCOPUS:33745366578

VL - 66

SP - 1073

EP - 1088

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 8

ER -